Major complications of post-chemotherapy retroperitoneal lymph node dissection in a contemporary cohort of patients with testicular cancer and a review of the literature
Tóm tắt
Post-chemotherapy retroperitoneal lymph node dissection (pc-RPLND) is one cornerstone in the clinical management of patients with nonseminomatous testicular germ cell tumours (GCT). A wide range of complication rates in this type of surgery is reported so far. We retrospectively evaluated the frequency of major complications by using the Clavien-Dindo classification and analysed the influence of various clinical factors on complication rates in pc-RPLND. We retrospectively analysed 146 GCT patients undergoing pc-RPLND. Complications of grade III–V according to the Clavien-Dindo classification occurring within 30 days after surgery were registered along with the following clinical factors: age, body mass index (BMI), duration of surgery, number of anatomic fields resected, side of primary tumour, histology of surgical specimen, histology of primary tumour, and total dose of cisplatin applied prior to surgery. For comparison, we also evaluated 35 chemotherapy-naïve patients with primary RPLND and 19 with laparoscopic RPLND. We analysed types and frequencies of the various complications as well as associations with clinical factors using descriptive statistical methods. A total of 14.4% grade III–IV complications were observed in pc-RPLND, and 8.6% and 5.3% in primary and in laparoscopic RPLND, respectively. There was no perioperative mortality. Lymphocele was the most frequent adverse event (16% of grade III–IV complications). Operation time > 270 min (p = 0.001) and vital cancer in the resected specimen (p = 0.02) were significantly associated with higher complication rates. Left-sided resection fields involved two-fold higher complication rates, barely missing statistical significance (p = 0.06). Pc-RPLND involves a grade III–V complication rate of 14.4%. Prolonged operation time and vital cancer in the residual mass are significantly associated with higher complication rates. The Clavien-Dindo classification system may allow inter-observer variation in rating complication grades, which may represent one reason for the wide range of reported RPLND complication rates. RPLND represents major surgery and surgeons active in this field must be competent to manage adverse events.
Tài liệu tham khảo
Hanna NH, Einhorn LH. Testicular cancer - discoveries and updates. N Engl J Med. 2014;371:2005–16.
Rajpert-De Meyts E, McGlynn KA, Okamoto K, Jewett MA, Bokemeyer C. Testicular germ cell tumours. Lancet. 2016;387:1762–74.
Kocher T. §1006. In: Die Krankheiten der männlichen Geschlechtsorgane. Stuttgart: Ferdinand Enke Verlag; 1887. p. 491–2.
Donohue JP. Evolution of retroperitoneal lymphadenectomy (RPLND) in the management of non-seminomatous testicular cancer (NSGCT). Urol Oncol. 2003;21:129–32.
Heidenreich A, Paffenholz P, Nestler T, Pfister D. Primary and postchemotherapy retroperitoneal lymphadenectomy for testicular cancer. Oncol Res Treat. 2018;41:370–8.
Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A, Laguna MP, Nicolai N, Oldenburg J. Guidelines on testicular cancer: 2015 Update. Eur Urol. 2015;68:1054–68.
Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, et al. Testicular cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17:1529–54.
Williams SB, McDermott DW, Dock W, Bahnson E, Berry AM, Steele GS, Richie JP. Retroperitoneal lymph node dissection in patients with high risk testicular cancer. J Urol. 2009;181:2097–102.
Dieckmann KP, Anheuser P, Kulejewski M, Gehrckens R, Feyerabend B. Is there still a place for retroperitoneal lymph node dissection in clinical stage 1 nonseminomatous testicular germ-cell tumours? A retrospective clinical study. BMC Urol. 2018;18:95. https://doi.org/10.1186/s12894-12018-10412-x.
Daneshmand S. Refining the role of primary retroperitoneal lymph node dissection in the management of early-stage testicular cancer. Curr Opin Urol. 2020;30:234.
Kunit T, Janetschek G. Minimally invasive retroperitoneal lymphadenectomy: current status. Urol Clin North Am. 2015;42:321–9.
Cary C, Masterson TA, Bihrle R, Foster RS. Contemporary trends in postchemotherapy retroperitoneal lymph node dissection: Additional procedures and perioperative complications. Urol Oncol. 2015;33:389 e315-321.
Tanaka T, Kitamura H, Kunishima Y, Takahashi S, Takahashi A, Masumori N, Itoh N, Tsukamoto T. Modified and bilateral retroperitoneal lymph node dissection for testicular cancer: peri- and postoperative complications and therapeutic outcome. Jpn J Clin Oncol. 2006;36:381–6.
Sheinfeld J, Herr HW. Role of surgery in management of germ cell tumor. Sem Oncol. 1998;25:203–9.
Subramanian VS, Nguyen CT, Stephenson AJ, Klein EA. Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancer. Urol Oncol. 2010;28:504–9.
Macleod LC, Rajanahally S, Nayak JG, Parent BA, Ramos JD, Schade GR, Holt SK, Dash A, Gore JL, Lin DW. Characterizing the morbidity of postchemotherapy retroperitoneal lymph node dissection for testis cancer in a national cohort of privately insured patients. Urology. 2016;91:70–6.
Albers P, Melchior D, Müller SC. Surgery in metastatic testicular cancer. Eur Urol. 2003;44:233–44.
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.
Poletajew S, Zapała L, Piotrowicz S, Wołyniec P, Sochaj M, Buraczyński P, Lisiński J, Swiniarski P, Radziszewski P, Association. RSoPU. Interobserver variability of Clavien-Dindo scoring in urology. Int J Urol. 2014;21:1274–8.
Mitropoulos D, Artibani W, Biyani CS, Bjerggaard Jensen J, Rouprêt M, Truss M. Validation of the Clavien-Dindo Grading System in Urology by the European Association of Urology Guidelines Ad Hoc Panel. Eur Urol Focus. 2018;4:608–13.
de la Rosette JJ, Opondo D, Daels FP, Giusti G, Serrano A, Kandasami SV, Wolf JSJ, Grabe M, Gravas S, Group. CPS. Categorisation of complications and validation of the Clavien score for percutaneous nephrolithotomy. Eur Urol. 2012;62:246–55.
Donohue JP, Foster RS, Rowland RG, Bihrle R, Jones J, Geier G. Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol. 1990;144:287–91.
Dieckmann KP, Gross AJ, Huland H. A test for the identification of relevant sympathetic nerve fibers during nerve-sparing retroperitoneal lymphadenectomy. J Urol. 1992;148:1450–2.
Souchon R, Krege S, Schmoll HJ, Albers P, Beyer J, Bokemeyer C, Classen J, Dieckmann KP, Hartmann M, Heidenreich A, et al. Interdisziplinärer Konsensus zur Diagnostik und Therapie von Hodentumoren. Ergebnisse einer Update-Konferenz auf Grundlage evidenzbasierter Medizin (EBM). Strahlenther Onkol. 2000;176:388–405.
Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, et al. European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I. Eur Urol. 2008;53:478–96.
Weissbach L, Boedefeld EA, Testicular tumor study group. Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified stagimng lymph node dissection in stage I. J Urol. 1987;138:77–82.
Pottek T. Retroperitoneale Lymphadenektomie beim Hodentumor. Urologe A. 2004;43:1514–20.
Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, Czerniak B, Kamat AM, Pisters LL. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer. 2006;107:1483–90.
Fléchon A, Tavernier E, Boyle H, Meeus P, Rivoire M, Droz JP. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour. BJU Int. 2010;106:779–85.
Luz MA, Kotb AF, Aldousari S, Brimo F, Tanguay S, Kassouf W, Aprikian AG. Retroperitoneal Lymph Node Dissection for Residual Masses after Chemotherapy in Nonseminomatous Germ Cell Testicular Tumor. World J Surg Oncol. 2010;8:97.
Wells H, Hayes MC, O'Brien T, Fowler S. Contemporary retroperitoneal lymph node dissection (RPLND) for testis cancer in the UK - a national study. BJU Int. 2017;119:91–9.
Hendry WF, Norman AR, Dearnaley DP, Fisher C, Nicholls J, Huddart RA, Horwich A. Metastatic nonseminomatous germ cell tumors of the testis: results of elective and salvage surgery for patients with residual retroperitoneal masses. Cancer. 2002;94:1668–76.
Djaladat H, Nichols C, Daneshmand S. Adjuvant Surgery in Testicular Cancer Patients Undergoing Postchemotherapy Retroperitoneal Lymph Node Dissection. Ann Surg Oncol. 2012;19:2388–93.
Considine S, Heaney R, Conroy R, Thornhill JA. Post-chemotherapy retroperitoneal lymph node dissection in the management of metastatic testis cancer: the 16-year experience in an Irish setting. Ir J Med Sci. 2016;185:901–7.
Dusaud M, Malavaud B, Bayoud Y, Sebe P, Hoepffner JL, Salomon L, Houlgatte A, Pignot G, Rigaud J, Fléchon A, et al. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study. J Surg Oncol. 2016;114:992–6.
Paffenholz P, Pfister D, Heidenreich A. Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours. Article in German. Urologe A. 2016;55:632–40.
Hiester A, Nini A, Fingerhut A, Große Siemer R, Winter C, Albers P, Lusch A. Preservation of ejaculatory function after postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in patients with testicular cancer: template vs. bilateral resection. Front Surg. 2019;5:80. https://doi.org/10.3389/fsurg.2018.00080 eCollection 02018.
Gerdtsson A, Håkansson U, Törnblom M, Jancke G, Negaard HFS, Glimelius I, Halvorsen D, Karlsdóttir Á, Haugnes HS, Andreassen KE, et al. Surgical complications in postchemotherapy retroperitoneal lymph node dissection for nonseminoma germ cell tumour: a population-based study from the Swedish Norwegian Testicular Cancer Group. Eur Urol Oncol. 2020;3:382–9.
Blok JM, Meijer RP, van der Poel HG, Bex A, van Vooren J, van Urk JJ, Horenblas S, Bosch JLHR. Additional surgical procedures and perioperative morbidity in post-chemotherapy retroperitoneal lymph node dissection for metastatic testicular cancer in two intermediate volume hospitals. World J Urol. 2020. https://doi.org/10.1007/s00345-020-03229-5 [Epub ahead of print].
Gels ME, Nijboer AP, Hoekstra HJ, Sleijfer DT, Molenaar WM, Plukker JT, Droste JH, Schraffordt Koops H. Complications of the post-chemotherapy resection of retroperitoneal residual tumour mass in patients with non-seminomatous testicular germ cell tumours. Br J Urol. 1997;79:263–8.
Tandstad T, Kollmannsberger CK, Roth BJ, Jeldres C, Gillessen S, Fizazi K, Daneshmand S, Lowrance WT, Hanna NH, Albany C, et al. Practice makes perfect: the rest of the story in testicular cancer as a model curable neoplasm. J Clin Oncol. 2017;35:3525–8.
Capitanio U, Jeldres C, Perrotte P, Isbarn H, Crépel M, Cloutier V, Baillargeon-Gagne S, Shariat SF, Duclos A, Arjane P, et al. Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors. Urology. 2009;74:373–7.
Albany C, Kesler K, Cary C. Management of Residual Mass in Germ Cell Tumors After Chemotherapy. Curr Oncol Rep. 2019;21:5. https://doi.org/10.1007/s11912-11019-10758-11916.
Lusch A, Albers P. Residual tumor resection (RTR). World J Urol. 2017;35:1185–90.
Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G, Daugaard G, Dieckmann KP, et al. ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Ann Oncol. 2018;29:1658–86.
Steyerberg EW, Gerl A, Fossa SD, Sleijfer DT, de Wit R, Kirkels WJ, Schmeller N, Clemm C, Habbema JD, Keizer HJ. Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer. J Clin Oncol. 1998;16:269–74.
Winter C, Pfister D, Busch J, Bingöl C, Ranft U, Schrader M, Dieckmann KP, Heidenreich A, Albers P. Residual tumor size and IGCCCG risk classification predict additional vascular procedures in patients with germ cell tumors and residual tumor resection: a multicenter analysis of the German Testicular Cancer Study Group. Eur Urol. 2012;61:403–9.
Patel HD, Ball MW, Cohen JE, Kates M, Pierorazio PM, Allaf ME. Morbidity of urologic surgical procedures: an analysis of rates, risk factors, and outcomes. Urology. 2015;85:552–9.
DeMaria EJ, Carmody BJ. Perioperative management of special populations: obesity. Surg Clin North Am. 2005;5:1283–9.
Bazurro S, Ball L, Pelosi P. Perioperative management of obese patient. Curr Opin Crit Care. 2018;24:560–7.
Slankamenac K, Graf R, Barkun J, Puhan MA, Clavien PA. The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Ann Surg. 2013;258:1–7.
Yamamoto T, Takahashi S, Ichihara K, Hiyama Y, Uehara T, Hashimoto J, Hirobe M, Masumori N. How do we understand the disagreement in the frequency of surgical site infection between the CDC and Clavien-Dindo classifications? J Infect Chemother. 2015;21:130–3.
Elkoushy MA, Luz MA, Benidir T, Aldousari S, Aprikian AG, Andonianm S. Clavien classification in urology: Is there concordance among post-graduate trainees and attending urologists? Can Urol Assoc J. 2013;7:179–84.
Rassweiler JJ, Rassweiler MC, Michel MS. Classification of complications:: Is the Clavien-Dindo classification the Gold standard? Eur Urol. 2012;62:256–60.
Katayama H, Kurokawa Y, Nakamura K, Ito H, Kanemitsu Y, Masuda N, Tsubosa Y, Satoh T, Yokomizo A, Fukuda H, Sasako M. Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria. Surg Today. 2016;46:668–85.
Vahlensieck W, Beltz L, Weissbach L. Retro- and intraperitoneal lymph fistula following semicastration and transperitoneal lymphadenectomy in testicular tumors (author's transl). Urol Int. 1973;28:453–8.
Vahlensieck EW, Jaeger N, Widman T. Ursachen, Prävention und Behandlung von Komplikationen der lymphadenektomie beim Hodentumorpatienten. Urologe A. 1985;24:137–41.